PMV Pharmaceuticals is a clinical-stage company focused on the development of precision oncology therapies targeting mutant p53 proteins
PMV Pharmaceuticals is a clinical-stage company focused on the development of precision oncology therapies targeting mutant p53 proteins. Their lead product candidate, rezatapopt, is designed for tumor-agnostic treatment and is being investigated for various cancers, including acute myeloid leukemia.